NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMAS

Author(s):
Klein, M.; Reijneveld, J.C.; Idbaih, A.; Taal, W.; Clement, P.M.; Vos, F. de; Wick, A.; Mulholland, P.; Taphoorn, M.J.B.; Lewis, J.; Weller, M.; Verschuere, T.; Golfinopoulos, V.; Gorlia, T.; Bent, M. van den
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-11-30
Language
English
Is part of
Neuro-Oncology (2017), Vol. 19, p. 139-139
hdl
1887/88286